Terminated PHASE2 INTERVENTIONAL 1-arm NCT00585416

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001)

Sponsor: Progen Pharmaceuticals

Interventions CGC-11047

Updated 7 times since 2017 Last updated: Sep 30, 2015 Started: Jun 30, 2006 Primary completion: Nov 30, 2007 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Further evaluation of phase I dosing

Listed as NCT00585416, this PHASE2 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Progen Pharmaceuticals, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE2
Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Progen Pharmaceuticals
University of Wisconsin, Madison

Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States